Get the Stockscreener App
5.02
2.90%
-0.15
Xeris Biopharma Holdings Inc stock is traded at $5.02, with a volume of 1.08M.
It is down -2.90% in the last 24 hours and up +6.58% over the past month.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
See More
Previous Close:
$5.17
Open:
$5.18
24h Volume:
1.08M
Relative Volume:
0.52
Market Cap:
$785.05M
Revenue:
$181.41M
Net Income/Loss:
$-59.56M
P/E Ratio:
-11.95
EPS:
-0.42
Net Cash Flow:
$-38.83M
1W Performance:
-1.76%
1M Performance:
+6.58%
6M Performance:
+45.51%
1Y Performance:
+96.48%
1-Day Range:
$4.99
$5.18
1-Week Range:
$4.99
$5.235
52-Week Range:
$2.095
$6.07
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
5.02 | 828.00M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Is Xeris Biopharma Holdings Inc. Stock a Good Fit for Conservative InvestorsGrowth Optimized Stock Radar - Newser
New York State Common Retirement Fund Boosts Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Why Xeris Biopharma Holdings Inc. stock attracts strong analyst attentionFree Financial Group - Metal.it
Cwm LLC Increases Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Is Xeris Biopharma Holdings Inc. a good long term investmentDouble or triple returns - PrintWeekIndia
Will Xeris Biopharma Holdings Inc. stock split in the near futureGame-changing capital returns - jammulinksnews.com
Xeris Biopharma Holdings Inc. Stock Analysis and ForecastFree Investment Case Studies - PrintWeekIndia
What analysts say about Xeris Biopharma Holdings Inc. stockFree Trend-Following Techniques - PrintWeekIndia
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
What drives Xeris Biopharma Holdings Inc. stock pricePowerful profit generation - jammulinksnews.com
How Xeris Biopharma Holdings Inc. stock performs during market volatilitySmall Risk Large Return Trades - Newser
Xponance Inc. Invests $57,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
how xeris biopharma holdings inc. stock performs during market volatilityMarket Timing Advice - Newser
why xeris biopharma holdings inc. stock attracts strong analyst attentionMassive Upside Selection - Newser
Brown Advisory Inc. Has $630,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
What makes Xeris Biopharma Holdings Inc. stock price move sharplyBreakout Momentum Stocks - Newser
A Piece Of The Puzzle Missing From Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) 25% Share Price Climb - simplywall.st
Xeris Biopharma's 7% Spike: Unraveling the Mysterious Move - AInvest
Wealth Enhancement Advisory Services LLC Has $172,000 Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma's 10% Spike: A Technical and Market Flow Deep Dive - AInvest
Xeris Biopharma (NASDAQ:XERS) versus Mangoceuticals (NASDAQ:MGRX) Head to Head Review - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Rhumbline Advisers Increases Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Wealth Enhancement Advisory Services LLC Raises Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing - Seeking Alpha
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 8.4% Following Insider Buying Activity - Defense World
Pallas Capital Advisors LLC Acquires New Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Squarepoint Ops LLC Has $138,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Two Sigma Advisers LP Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Leerink Partnrs Estimates Xeris Biopharma FY2025 Earnings - Defense World
Leerink Partnrs Forecasts Lower Earnings for Xeris Biopharma - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Down 5.5%Should You Sell? - MarketBeat
Leerink Partners raises Xeris Pharmaceuticals stock price target By Investing.com - Investing.com UK
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):